Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +2.52% | +16.07% | -21.59% |
Sales 2024 * | - | Sales 2025 * | 25.86M 2.07B | Capitalization | 83.21M 6.65B |
---|---|---|---|---|---|
Net income 2024 * | -69M -5.51B | Net income 2025 * | -69M -5.51B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.22 x |
P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-2.18
x | Employees | 54 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84% |
Latest transcript on Leap Therapeutics, Inc.
1 day | +2.52% | ||
1 week | +16.07% | ||
Current month | +22.18% | ||
1 month | +22.18% | ||
3 months | +33.20% | ||
6 months | +132.14% | ||
Current year | -21.59% |
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 31/12/10 |
Chris Mirabelli
CHM | Chairman | 69 | 31/12/10 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 23/08/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 31/12/15 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 31/12/16 |
Chris Mirabelli
CHM | Chairman | 69 | 31/12/10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.25 | +2.52% | 403,202 |
25/04/24 | 3.17 | -3.65% | 213,233 |
24/04/24 | 3.29 | +2.81% | 200,614 |
23/04/24 | 3.2 | -0.31% | 89,131 |
22/04/24 | 3.21 | +14.64% | 328,700 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.59% | 83.21M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.82% | 22.15B | |
-17.37% | 21.02B | |
-8.05% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LPTX Stock